LGD4033: Minimum Effective Dose

Conclusion: decreasing marginal LBM% at higher doses. Simply - more is not necessary better, especially for those doing a SARM only cycle and dealing with suppression sides. Stick to 5mg ED until we get more data from future trials.

In Nov 2017 announced the results of a Phase 2 clinical trial on what we commonly refer to as LGD4033, but is officially known as VK5211. The study was a randomized, double-blind, placebo-controlled, parallel group, international study designed to evaluate the efficacy, safety and tolerability of VK5211 in patients recovering from hip fracture surgery - not a perfect group for our purposes but we'll take what data we can get and be extremely grateful.

A total of 108 patients were randomized to receive once-daily VK5211 doses of 0.5 mg, 1.0 mg, 2.0 mg, or placebo for 12 weeks.

LBM% gains are summarized as follows: 0.5mg - 4.8%; 1.0mg - 7.2%; 2.0mg - 9.1%

If I take an admittedly enormous and completely unscientific liberty by filling in the gap at the 1.5mg dosage we see a chart that shows declining efficiency.. This is far from conclusive however, as the sample group had broken hips and did not exactly engage in squats and deadlifts. Could a group that is working out and utilizing VK5211 for PE get better LBM% gains at higher doses? Probably and only up to a point. It's an unknown, and without more data I would recommend 5mg or less ED for the moment.